AKT1 and hepatocellular carcinoma: Importantly, the PTEN agonist, Oroxin B (OB), blocked the DDX56-mediated PTEN-AKT signaling pathway, suggesting that treating HCC patients with a PTEN agonist, such as OB, may result in a beneficial therapeutic intervention.